Trial Profile
A trial of tipapkinogene sovacivec [TG-4001] in combination with immune checkpoint inhibitors in patients with advanced HPV-induced cancer
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 27 Sep 2016
Price :
$35
*
At a glance
- Drugs Tipapkinogene sovacivec (Primary) ; Immunomodulators
- Indications Head and neck cancer; Human papillomavirus infections
- Focus Therapeutic Use
- Sponsors Transgene
- 05 Sep 2016 According to a Transgene media release, this study is expected to begin in the second half of 2017.
- 30 Mar 2015 New trial record